Sikander Ailawadhi, MD

Sikander Ailawadhi, MD, is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Jacksonville, Florida

Articles

Biological Determinants of Health in Multiple Myeloma

September 23rd 2022

Focused discussion on the biological determinants of multiple myeloma and how its prevalence is reflected in racial and ethnic minority groups.

Overview of Multiple Myeloma and Health Equity

September 23rd 2022

Joseph Mikhael, MD, spearheads an overview on the prevalence of multiple myeloma in racial and ethnic minority groups in the context of health equity.

Dr. Ailawadhi on the Examination of Iopofosine I-131 in Waldenström Macroglobulinemia

May 20th 2022

Sikander Ailawadhi, MD, discusses the examination of iopofosine I-131 (CLR 131) in Waldenström macroglobulinemia.

Dr. Ailawadhi on the Rationale for Evaluating Lisaftoclax in CLL

October 19th 2021

Sikander Ailawadhi, MD, discusses the rationale for evaluating lisaftoclax in chronic lymphocytic leukemia in an early phase 1 study.

Dr. Ailawadhi on Next Steps With Lisaftoclax in CLL and Other Hematologic Malignancies

October 15th 2021

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia and other hematologic malignancies.

Dr. Ailawadhi on the Results of a First-in-Human Study of Lisaftoclax in Hematologic Malignancies

September 20th 2021

Sikander Ailawadhi, MD, discusses the results of a first-in-human, early phase 1 study of lisaftoclax in patients with hematologic malignancies.

Dr. Ailawadhi on Patient Considerations for BTK Inhibitors in Waldenström Macroglobulinemia

September 3rd 2021

Sikander Ailawadhi, MD, discusses patient considerations for BTK inhibitors in Waldenström macroglobulinemia.

Dr. Ailawadhi on Next Steps With Lisaftoclax in CLL

June 30th 2021

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia.

Dr. Ailawadhi on the Safety Profile of Lisaftoclax in CLL

June 25th 2021

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Dr. Ailawadhi on the Rationale to Evaluate Lisaftoclax in CLL

June 9th 2021

Sikander Ailawadhi, MD, discusses the rationale to evaluate lisaftoclax in chronic lymphocytic leukemia.

Dr. Ailawadhi on the Efficacy of Lisaftoclax in Hematologic Malignancies

June 7th 2021

Sikander Ailawadhi, MD, discusses the activity of lisaftoclax in patients with hematologic malignancies.

Dr. Ailawadhi on Potential Combination Strategies in Multiple Myeloma

January 26th 2021

Sikander Ailawadhi, MD, discusses potential combination strategies with selinexor and belantamab mafodotin-blmf in multiple myeloma.

Dr. Ailawadhi on the Emergence of T-Cell Engagers in Multiple Myeloma

January 13th 2021

Sikander Ailawadhi, MD, discusses the emergence of T-cell engagers in multiple myeloma.

Dr. Ailawadhi on the Potential Role of Melflufen in Multiple Myeloma

January 7th 2021

Sikander Ailawadhi, MD, discusses the potential role of melflufen in multiple myeloma.

Dr. Ailawadhi on the Integration of Selinexor in Relapsed/Refractory Multiple Myeloma

January 5th 2021

Sikander Ailawadhi, MD, discusses the integration of selinexor into the treatment landscape of relapsed/refractory multiple myeloma.